FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 339:625-627 August 27, 1998 Number 9 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Kaufman, J. S. Related Article by Besarab, A. PubMed Citation

Currently, there are approximately 200,000 patients with end-stage renal disease in the United States who require dialysis therapy to stay alive, and dialysis is initiated in nearly 70,000 new patients each year.¹ About 90 percent of patients undergoing dialysis have anemia as a result of erythropoietin deficiency. Anemia contributes substantially to morbidity and mortality among these patients, and the introduction of recombinant human erythropoietin (epoetin) therapy in 1989 significantly improved the quality of life, reduced the need for red-cell transfusions,² and improved measures of various physiologic functions such as maximal exercise capacity and cognition. Although epoetin is expensive, costing the . . . [Full Text of this Article]

References

This article has been cited by other articles:

• Spinowitz, B. S. (2008). Anemia management in patients on peritoneal dialysis: efficacy and safety of epoetin {delta}. haematol 93: 761-764 [Abstract] [Full Text]  
• Auerbach, M. (2008). Should Intravenous Iron Be the Standard of Care in Oncology?. JCO 26: 1579-1581 [Full Text]  
• Auerbach, M., Rodgers, G. M. (2007). Intravenous Iron. NEJM 357: 93-94 [Full Text]  
• Fink, J. C., Hsu, V. D., Zhan, M., Walker, L. D., Mullins, C. D., Jones-Burton, C., Langenberg, P., Seliger, S. L. (2007). Center Effects in Anemia Management of Dialysis Patients. J. Am. Soc. Nephrol. 18: 646-653 [Abstract] [Full Text]  
• Davidson, S. M., Yellon, D. M. (2006). Dissecting out the mechanism of cardioprotection by endogenous erthyropoietin using genetic engineering. Cardiovasc Res 71: 408-410 [Full Text]  
• Weiss, G., Goodnough, L. T. (2005). Anemia of Chronic Disease. NEJM 352: 1011-1023 [Full Text]  
• Costa, J., Crausman, R. S., Weinberg, M. S. (2004). Acute and Chronic Renal Failure. J. Am. Podiatr. Med. Assoc. 94: 168-176 [Abstract] [Full Text]  
• Goodnough, L. T., Skikne, B., Brugnara, C. (2000). Erythropoietin, iron, and erythropoiesis. Blood 96: 823-833 [Abstract] [Full Text]  
• MORENO, F., SANZ-GUAJARDO, D., LOPEZ-GOMEZ, J. M., JOFRE, R., VALDERRABANO, F. (2000). Increasing the Hematocrit Has a Beneficial Effect on Quality of Life and Is Safe in Selected Hemodialysis Patients. J. Am. Soc. Nephrol. 11: 335-342 [Abstract] [Full Text]  
• (1998). Hematocrit in Cardiac Patients Receiving Hemodialysis. Journal Watch Cardiology 1998: 8-8 [Full Text]